Клиническая эффективность и безопасность линаглиптина у пациентов с сахарным диабетом 2-го типа
https://doi.org/10.21518/2079-701X-2016-3-24-29
Аннотация
Лечение сахарного диабета 2-го типа (СД2) - это серьезная проблема, заставляющая искать новые подходы к улучшению результатов фармакотерапии заболевания. Последние успехи в области диа-бетологии связаны с инкретин-направленной терапией. Наряду с традиционными дефектами (инсу-линорезистентность, дисфункция р-клеток), существенный вклад в развитие и прогрессирование заболевания вносит сниженный «эффект инкретинов». Концепция сниженного «эффекта инкрети-нов» послужила основанием для разработки и внедрения в клиническую практику инновационного направления - применение лекарственных средств, действие которых основано на «эффектах инкретинов», - глюкагоноподобного пептида-1 (ГПП-1) и глюкозозависимого инсулинотропного полипептида (ГИП) [12, 17].
Об авторах
Е. В. Бирюкова
Московский государственный медико-стоматологический университет им. А.И. Евдокимова
Россия
Россия
А. М. Мкртумян
Московский государственный медико-стоматологический университет им. А.И. Евдокимова
Россия
Россия
Список литературы
1. Алгоритмы специализированной медицинской помощи больных сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой, Вып. 7. М., 2015.
2. Инструкция по медицинскому применению лекарственного препарата Тражента. Регистрационное удостоверение: ЛП-001430.
3. Amiel SA, Dixon T, Mann R, Jameson K. Hypoglycaemia in type 2 diabetes. Diabet Med, 2008, 25: 245-254.
4. Aroda VR, Henry RR, Han J et al. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: Meta-analysis and systematic review. Clinical Therapeutics, 2012, 34(6): 1247-1258.
5. Ban K, Hui S, Drucker DJ, Husain M. Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin-based therapies. J Am Soc Hypertens, 2009, 3: 245-259.
6. Barnett A, Patel S, Harper R et al. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, doubleblind, placebo-controlled phase III trial with a 34-week active-controlled extension. Diabetes Obes Metab, 2012, 14(12): 1145-1154.
7. Ban K, Hui S, Drucker DJ, Husain M. Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin-based therapies. J Am Soc Hypertens, 2009, 3: 245-259.
8. Blech S, Ludwig-Schwellinger E, Grafe-Mody EU et al. The metabolism and disposition of oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos, 2010, 38: 667-678.
9. Bloomgarden ZT. Cardiovascular disease in diabetes. Diabetes Care, 2008, 31(6): 1260-1266.
10. Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes, Obesity and Metabolism, 2011, 13: 7-18.
11. Forst T, Uhlig-Laske B, Ring A et aL Linagliptin (BI 1256), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled type-2 diabetes. Diabetic Med, 2010, 27: 1409-1419.
12. Gallwitz B, Rosenstock J, Rauch T et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet, 2012, 380(9840): 475-483.
13. Garcia-Compean D, Jaquez-Ouintana JO, Gonzalez-Gonzalez JA, Maldonado-Garza H. Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management. World J Gastroenterol, 2009, 15: 280-8.
14. Gomis R, Owens DR, Taskinen MR et al. Long-term safety and efficacy of linagliptin as mono-therapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extension. Int J Clin Pract., 2012, 66(8): 731-740.
15. Graefe-Mody U, Friedrich C, Port A et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obesity Metab, 2011, 13(10): 939-946.
16. Graefe-Mody U, Rose P, Retlich S et al. Pharmacokinetics of linagliptin in subjects with hepatic Impairment. Br J Clin Pharmacol., 2012. doi: 10.1111/j.1365-2125.2012.04173.x.
17. Groop P-H, Cooper M, Perkovic V, Emser A et al. Effects of the DPP-4 inhibitor linagliptin on albuminuria in patients with type 2 diabetes and diabetic nephropathy. Diabetologia, 2012, 55(Suppl 1): S20.
18. Gross JL, de Azevedo MJ, Silveiro SP et al. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care, 2005, 28: 164-172.
19. Haak T, Meinicke T, Jones R et al. Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab, 2012, 14: 565-574.
20. Johansen OE, Neubacher D, von Eynatten M et al. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc Diabetol., 2012, 10, 11: 3.
21. Koro CE, Lee BH, Bowlin SJ. Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States. Clin Ther, 2009, 31: 2608-2617.
22. Lewin AJ, Arvay L, Liu D et al. Efficacy and tolera-bility of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicent-er, randomized, double-blind, placebo-controlled trial. Clin Ther, 2012, 1909-1919: e1915.
23. Malesker MA. Optimizing antidiabetic treatment options for patients with type 2 diabetes mellitus and cardiovascular comorbidities. Pharmacotherapy, 2008, 28(2): 193-206.
24. McGill JB, Sloan L, Newman J et al. Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, doubleblind, placebo-controlled study. Diabetes Care, 2013, 36(2): 237-244.
25. Moen MF, Zhan M, Hsu VH. Frequency of hypogly-cemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol., 2009, 4(6): 1121-1127
26. Neumiller JJ. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. J Am Pharm Assoc, 2009, 49 (Suppl. 1): S16-S29.
27. Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepato-cellular carcinoma. Dig Liver Dis, 2010, 42(Suppl 3): S206-14.
28. Philippe J, Raccah D. Treating type 2 diabetes: how safe are current therapeutic agent? Int J Clin Pract, 2009, 63: 321-32.
29. Pratley RE, Salsali A. Inhibition of DPP-4: a new therapeutic approach for the treatment of type diabetes. Curr Med Res Opin, 2007, 23: 919-931.
30. Ring A, Port A, Graefe-Mody EU et al. The DPP-4 inhibitor linagliptin does not prolong the OT interval at therapeutic and supratherapeutic doses. Br J Clin Pharmacol, 2011, 72: 39-50.
31. Scheen AJ. Dipeptidylpeptidase-4 inhibitors (gliptins): Focus on drug-drug interactions. Clin Pharmacokinet, 2010, 49: 573-588.
32. Schernthaner G, Barnett AH, Emser A et al. Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus. Diabetes Obes Metab 2012, 14(5): 470-478.
33. Schernthaner G, Barnett AH, Patel S et al. Safety and efficacy of the dipeptidyl pepti-dase-4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged £ 65 years. Diabetes Obes Metab, 2014, 16(11): 1078-86.
34. Taskinen MR, Rosenstock J, Tamminen I et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type-2 diabetes: A randomized, double-blind, placebo-controlled study. Diabetes Obesity Metab, 2011, 13: 65-74.
35. Thrasher J, Kountz DS, Crowe S, Woerle HJ, von Eynatten M. Efficacy and safety of the dipepti-dyl peptidase-4 inhibitor linagliptin in black/ African American patients with type 2 diabetes: Pooled analysis from eight Phase III trials. Postgrad Med, 2015, 127(5): 419-28.
36. Tielmans A, Laloi-Michelin M, Coupaye M et al. Drug treatment of type 2 diabetes. Presse Med, 2007, 36(2 Pt 2): 269-78.
37. Vilsboll T, Holst JJ. Incretins, insulin secretion and type 2 diabetes mellitus. Diabetologia, 2004, 47: 357-366.
38. Widenmaier SB, Sampaio AV, Underhill TM et al. Noncanon-ical activation of Akt/protein kinase B in (betaj-cells by the incretin hormone glucose-dependent insulinotropic poly peptide. J. Biol. Chem., 2009, 10764-10773.
39. Yki-Jarvinen H, Rosenstock J, Duran-Garcia S et al. Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes. Diabetes Care, 2013, 36: 3875-3881.
40. Zeng Z, Choi DS, Mohan V, Emser A et al. Efficacy and safety of linagliptin as monothera-py or add-on treatment in Asian patients with suboptimal glycemic control: a pooled analysis. Curr Med Res Opin, 2015 Jan, 31(1): 99-106.
41. Algorithms of specialized medical care to patients with diabetes mellitus. Ed. by I.I. Dedov, M.V. Shestakova, Vol. 7. М., 2015.
42. Tradjenta: instruction for medical use. Registration certificate: LP-001430.
Рецензия
Для цитирования:
Бирюкова ЕВ, Мкртумян АМ. Клиническая эффективность и безопасность линаглиптина у пациентов с сахарным диабетом 2-го типа. Медицинский Совет. 2016;(3):24-29. https://doi.org/10.21518/2079-701X-2016-3-24-29
For citation:
Biryukova EV, Mkrtumyan AM. Clinical efficacy and safety of linagliptin in patients with diabetes type 2. Meditsinskiy sovet = Medical Council. 2016;(3):24-29. (In Russ.) https://doi.org/10.21518/2079-701X-2016-3-24-29
Просмотров: 658
Послать статью по эл. почте 